The Role of Nanotherapy in Head and Neck Squamous Cell Carcinoma by Targeting Tumor Microenvironment

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Jun 9

PMID 37292204

Authors

Ye Zhang

Pengbo Dong

Lu Yang

Affiliations

Soon will be listed here.

Abstract

Head and neck squamous cell carcinomas (HNSCCs) refers to a group of highly malignant and pathogenically complex tumors. Traditional treatment methods include surgery, radiotherapy, and chemotherapy. However, with advancements in genetics, molecular medicine, and nanotherapy, more effective and safer treatments have been developed. Nanotherapy, in particular, has the potential to be an alternative therapeutic option for HNSCC patients, given its advantageous targeting capabilities, low toxicity and modifiability. Recent research has highlighted the important role of the tumor microenvironment (TME) in the development of HNSCC. The TME is composed of various cellular components, such as fibroblasts, vascular endothelial cells, and immune cells, as well as non-cellular agents such as cytokines, chemokines, growth factors, extracellular matrix (ECM), and extracellular vesicles (EVs). These components greatly influence the prognosis and therapeutic efficacy of HNSCC, making the TME a potential target for treatment using nanotherapy. By regulating angiogenesis, immune response, tumor metastasis and other factors, nanotherapy can potentially alleviate HNSCC symptoms. This review aims to summarize and discuss the application of nanotherapy that targets HNSCC's TME. We highlight the therapeutic value of nanotherapy for HNSCC patients.

Citing Articles

Recurrent Sinonasal Squamous Cell Carcinoma: Current Insights and Treatment Advances.

Kravitz M, Annadata V, Ilyaev B, Tong C, Fastenburg J, Chaskes M Cancers (Basel). 2025; 17(1.

PMID: 39796633 PMC: 11718787. DOI: 10.3390/cancers17010004.

Precision USPIO-PEG-SLe Nanotheranostic Agent Targeted Photothermal Therapy for Enhanced Anti-PD-L1 Immunotherapy to Treat Immunotherapy Resistance.

Li T, Guo L, Li J, Mu X, Liu L, Song S Int J Nanomedicine. 2024; 19:1249-1272.

PMID: 38348177 PMC: 10859766. DOI: 10.2147/IJN.S445879.

Role of Microenvironmental Components in Head and Neck Squamous Cell Carcinoma.

Jumaniyazova E, Lokhonina A, Dzhalilova D, Kosyreva A, Fatkhudinov T J Pers Med. 2023; 13(11).

PMID: 38003931 PMC: 10672525. DOI: 10.3390/jpm13111616.

Lipid-Coated Polymeric Nanoparticles for the Photodynamic Therapy of Head and Neck Squamous Cell Carcinomas.

Roschenko V, Ayoub A, Engelhardt K, Schafer J, Amin M, Preis E Pharmaceutics. 2023; 15(10).

PMID: 37896172 PMC: 10610306. DOI: 10.3390/pharmaceutics15102412.

References

Moon E, Petersson K, Olcina M . The importance of hypoxia in radiotherapy for the immune response, metastatic potential and FLASH-RT. Int J Radiat Biol. 2021; 98(3):439-451. PMC: 7612434. DOI: 10.1080/09553002.2021.1988178. View

Yang G, Xu L, Chao Y, Xu J, Sun X, Wu Y . Hollow MnO as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses. Nat Commun. 2017; 8(1):902. PMC: 5638920. DOI: 10.1038/s41467-017-01050-0. View

Chithra A, Sekar R, Kumar P, Padmalaya G . A review on removal strategies of microorganisms from water environment using nanomaterials and their behavioural characteristics. Chemosphere. 2022; 295:133915. DOI: 10.1016/j.chemosphere.2022.133915. View

Kato Y, Ozawa S, Miyamoto C, Maehata Y, Suzuki A, Maeda T . Acidic extracellular microenvironment and cancer. Cancer Cell Int. 2013; 13(1):89. PMC: 3849184. DOI: 10.1186/1475-2867-13-89. View

Hoffmann C, Calugaru V, Borcoman E, Moreno V, Calvo E, Liem X . Phase I dose-escalation study of NBTXR3 activated by intensity-modulated radiation therapy in elderly patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynx. Eur J Cancer. 2021; 146:135-144. DOI: 10.1016/j.ejca.2021.01.007. View

Rauf A, Abu-Izneid T, Khalil A, Hafeez N, Olatunde A, Rahman M . Nanoparticles in clinical trials of COVID-19: An update. Int J Surg. 2022; 104:106818. PMC: 9359769. DOI: 10.1016/j.ijsu.2022.106818. View

Huff T, Tong L, Zhao Y, Hansen M, Cheng J, Wei A . Hyperthermic effects of gold nanorods on tumor cells. Nanomedicine (Lond). 2007; 2(1):125-32. PMC: 2597406. DOI: 10.2217/17435889.2.1.125. View

Allen J, Hames R, Mastroianni N, Greenstein A, Weed S . Evaluation of the matrix metalloproteinase 9 (MMP9) inhibitor Andecaliximab as an Anti-invasive therapeutic in Head and neck squamous cell carcinoma. Oral Oncol. 2022; 132:106008. DOI: 10.1016/j.oraloncology.2022.106008. View

Yu G, Mao L, Wu L, Deng W, Bu L, Liu J . Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma. Cell Mol Life Sci. 2018; 75(22):4223-4234. PMC: 11105240. DOI: 10.1007/s00018-018-2863-3. View

10.

Fan H, Zhu Z, Zhang W, Yin Y, Tang Y, Liang X . Light stimulus responsive nanomedicine in the treatment of oral squamous cell carcinoma. Eur J Med Chem. 2020; 199:112394. DOI: 10.1016/j.ejmech.2020.112394. View

11.

Xu Y, Fourniols T, Labrak Y, Preat V, Beloqui A, des Rieux A . Surface Modification of Lipid-Based Nanoparticles. ACS Nano. 2022; 16(5):7168-7196. DOI: 10.1021/acsnano.2c02347. View

12.

Cui J, Wang H, Zhang X, Sun X, Zhang J, Ma J . Exosomal miR-200c suppresses chemoresistance of docetaxel in tongue squamous cell carcinoma by suppressing TUBB3 and PPP2R1B. Aging (Albany NY). 2020; 12(8):6756-6773. PMC: 7202518. DOI: 10.18632/aging.103036. View

13.

Li Y, Zhao L, Li X . Hypoxia and the Tumor Microenvironment. Technol Cancer Res Treat. 2021; 20:15330338211036304. PMC: 8358492. DOI: 10.1177/15330338211036304. View

14.

Mody M, Rocco J, Yom S, Haddad R, Saba N . Head and neck cancer. Lancet. 2021; 398(10318):2289-2299. DOI: 10.1016/S0140-6736(21)01550-6. View

15.

Satapathy S, Nayak A, Siddharth S, Das S, Nayak D, Kundu C . Metallic gold and bioactive quinacrine hybrid nanoparticles inhibit oral cancer stem cell and angiogenesis by deregulating inflammatory cytokines in p53 dependent manner. Nanomedicine. 2018; 14(3):883-896. DOI: 10.1016/j.nano.2018.01.007. View

16.

Ponkshe P, Feng S, Tan C . Inhalable liposomes for treating lung diseases: clinical development and challenges. Biomed Mater. 2021; 16(5). DOI: 10.1088/1748-605X/ac0c0c. View

17.

Kamba T, McDonald D . Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007; 96(12):1788-95. PMC: 2359962. DOI: 10.1038/sj.bjc.6603813. View

18.

Niland S, Riscanevo A, Eble J . Matrix Metalloproteinases Shape the Tumor Microenvironment in Cancer Progression. Int J Mol Sci. 2022; 23(1). PMC: 8745566. DOI: 10.3390/ijms23010146. View

19.

He G, Nie J, Liu X, Ding Z, Luo P, Liu Y . Zinc oxide nanoparticles inhibit osteosarcoma metastasis by downregulating β-catenin via HIF-1α/BNIP3/LC3B-mediated mitophagy pathway. Bioact Mater. 2022; 19:690-702. PMC: 9112061. DOI: 10.1016/j.bioactmat.2022.05.006. View

20.

Liang R, Liu L, He H, Chen Z, Han Z, Luo Z . Oxygen-boosted immunogenic photodynamic therapy with gold nanocages@manganese dioxide to inhibit tumor growth and metastases. Biomaterials. 2018; 177:149-160. DOI: 10.1016/j.biomaterials.2018.05.051. View